Biotest AG (BIO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Biotest AG (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10000
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biotest AG (Biotest) provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary, Spain and in Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.

Biotest AG (BIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10
Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biotest AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12
Biotest Enters Into Research Agreement With EpiVax 13
Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15
Licensing Agreements 16
Affibody Enters into Licensing Agreement with Biotest 16
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18
CEVEC Pharma Enters into Licensing Agreement with Biotest 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
Equity Offering 21
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
Biotest Completes Rights Offering Of Preference Shares For US$99.5 Million 23
Asset Transactions 24
ADMA Biologics Acquires Certain Assets from Biotest Pharma 24
Acquisition 26
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Biotest AG – Key Competitors 27
Biotest AG – Key Employees 28
Biotest AG – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 32
Strategy And Business Planning 32
Jun 20, 2018: Biotest opens third plasma collection centre in Czech Republic 32
Jan 24, 2018: Biotest opens second plasma collection center in the Czech Republic 33
May 16, 2017: Biotest opens seventh plasma collection center in Hungary 34
Financial Announcements 35
Aug 14, 2018: Biotest sales increase to EUR 200.7 million in the first half of 2018 35
Mar 22, 2018: Biotest reaches 2017 profit guidance 36
Nov 14, 2017: Biotest generates revenues of EUR 377.8 million in the first nine months of 2017 37
May 10, 2017: Biotest will realize EUR 110.5 million in the first quarter of 2017 38
Product News 39
05/03/2018: New data from Biotest’s monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors 39
Other Significant Developments 40
Oct 11, 2017: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Biotest AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biotest AG, Deals By Therapy Area, 2012 to YTD 2018 9
Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10
Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12
Biotest Enters Into Research Agreement With EpiVax 13
Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15
Affibody Enters into Licensing Agreement with Biotest 16
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18
CEVEC Pharma Enters into Licensing Agreement with Biotest 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
Biotest Completes Rights Offering Of Preference Shares For US$99.5 Million 23
ADMA Biologics Acquires Certain Assets from Biotest Pharma 24
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Biotest AG, Key Competitors 27
Biotest AG, Key Employees 28
Biotest AG, Other Locations 29
Biotest AG, Subsidiaries 30

List of Figures
Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Biotest AG (BIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析
    Summary CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the t …
  • Ceapro Inc (CZO)-製薬・医療分野:企業M&A・提携分析
    Summary Ceapro Inc (Ceapro) is a biotechnology company which focuses on the development of extraction technology for use in the production of extracts and active ingredients from oats and other renewable plant resources. These extracts find application in therapeutic products for both humans and ani …
  • Acciona SA (ANA):電力:M&Aディール及び事業提携情報
    Summary Acciona SA (Acciona) is a provider of sustainable solutions for infrastructure and renewable energy projects. The company develops and manages infrastructure, renewable energy, water, and other facilities. Its operations cover the whole value chain, from design and construction to operation …
  • MedImmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune Ltd (MedImmune), formerly Cambridge Antibody Technology Ltd, is a subsidiary of AstraZeneca Plc, is a research and development company that develops and commercializes small molecule and biologic prescription medicines for the prevention of respiratory tract disease caused by respi …
  • Spectrum Pharmaceuticals Inc (SPPI)-製薬・医療分野:企業M&A・提携分析
    Summary Spectrum Pharmaceuticals Inc (Spectrum) is a biotechnology company that develops and commercializes a pipeline of late-stage clinical and commercial products with focus on hematology and oncology. The company’s marketed drugs include Fusilev (levoleucovorin); Folotyn (pralatrexate injection) …
  • Time Inc.:企業のM&A・事業提携・投資動向
    Time Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Time Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Dairyland Power Cooperative:発電所・企業SWOT分析
    Dairyland Power Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Hutchinson SA:企業の戦略的SWOT分析
    Hutchinson SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • BioVentrix Inc-医療機器分野:企業M&A・提携分析
    Summary BioVentrix Inc (BioVentrix) is a medical device company that develops congestive heart failure treatment solutions. The company provides revivent myocardial anchoring systems that restore the size, volume and resulting function of the left ventricle for improving cardiac function in heart fa …
  • Sitara Chemical Industries Ltd (SITC):企業の財務・戦略的SWOT分析
    Sitara Chemical Industries Ltd (SITC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Allison Transmission Holdings Inc:企業の戦略・SWOT・財務情報
    Allison Transmission Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Allison Transmission Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Bridgford Foods Corporation:企業の戦略・SWOT・財務情報
    Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • PaxVax Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PaxVax Inc (PaxVax) is a vaccine company that develops and commercializes specialty vaccines against infectious diseases. The company develops scalable, and oral vaccines. Its activities include early-stage preclinical research and development, clinical study support, drug product manufactur …
  • TPI Triunfo Participacoes e Invest. SA (TPIS3):企業の財務・戦略的SWOT分析
    TPI Triunfo Participacoes e Invest. SA (TPIS3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Black Rock Mining Ltd (BKT):電力:M&Aディール及び事業提携情報
    Summary Black Rock Mining Ltd (BRML), formerly Green Rock Energy Ltd, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of graphite properties. It holds interest in Mahenge Graphite Project which includes high-grade flake g …
  • U.S. Stem Cell Inc (USRM):製薬・医療:M&Aディール及び事業提携情報
    Summary U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal f …
  • OpGen Inc (OPGN)-製薬・医療分野:企業M&A・提携分析
    Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, s …
  • Luitpold Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Luitpold Pharmaceuticals Inc (Luitpold), a subsidiary of Daiichi Sankyo Company Ltd is a manufacturer and marketer of drugs and medical devices. The company provides injectable parenteral medications that are used in pharmacy admixtures and nutrient solutions, antidotes, critical care drugs, …
  • Egdon Resources Plc (EDR):企業の財務・戦略的SWOT分析
    Summary Egdon Resources Plc (Egdon) is oil and gas company that offers exploration and production services. The company explores and develops petroleum and natural gas assets in East Midlands, North East England, North West England, and Southern England, the UK. Its project site includes Wressle, No …
  • Willamette Valley Vineyards, Inc.:企業の戦略・SWOT・財務情報
    Willamette Valley Vineyards, Inc. - Strategy, SWOT and Corporate Finance Report Summary Willamette Valley Vineyards, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆